MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type

Several randomized trials have demonstrated non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations can achieve favorable clinical outcomes on treatment with EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation is considered as a predictive mark...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Li, Jiayu, Li, Xuefei, Ren, Shengxiang, Chen, Xiaoxia, Zhang, Yishi, Zhou, Fei, Zhao, Mingchuan, Zhao, Chao, Chen, Xiu, Cheng, Ningning, Zhao, Yinmin, Zhou, Caicun, Hirsch, Fred R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2014
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4202169/
https://ncbi.nlm.nih.gov/pubmed/25277203
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg